TY - JOUR
T1 - New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC)
T2 - from preclinical to phase I clinical trials
AU - Rocco, Danilo
AU - Gregorc, Vanesa
AU - Della Gravara, Luigi
AU - Lazzari, Chiara
AU - Palazzolo, Giovanni
AU - Gridelli, Cesare
N1 - Funding Information:
This paper was not funded.
Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Introduction: The development of immune checkpoint inhibitors (ICI) has represented a revolution in the treatment of non-small cell lung cancer (NSCLC) and has established a new standard of care for different settings. However, through adaptive changes, cancer cells can develop resistance mechanisms to these drugs, hence the necessity for novel immunotherapeutic agents. Areas covered: This paper explores the immunotherapeutics currently under investigation in phase I clinical trials for the treatment of NSCLC as monotherapies and combination therapies. It provides two comprehensive tables of phase I agents which are listed according to target, drug, drug class, mechanism of action, setting, trial identifier and trial status. A comprehensive literature search was carried out to identify eligible studies from MEDLINE/PubMed and ClinicalTrials.gov. Expert opinion: A key hurdle to success in this field is our limited understanding of the synergic interactions of the immune targets in the context of the TME. While we can recognize the links between inhibitors and some particularly promising new targets such as TIM-3 and LAG3, we continue to develop approaches to exploit their interactions to enhance the immune response of the patient to tumor cells.
AB - Introduction: The development of immune checkpoint inhibitors (ICI) has represented a revolution in the treatment of non-small cell lung cancer (NSCLC) and has established a new standard of care for different settings. However, through adaptive changes, cancer cells can develop resistance mechanisms to these drugs, hence the necessity for novel immunotherapeutic agents. Areas covered: This paper explores the immunotherapeutics currently under investigation in phase I clinical trials for the treatment of NSCLC as monotherapies and combination therapies. It provides two comprehensive tables of phase I agents which are listed according to target, drug, drug class, mechanism of action, setting, trial identifier and trial status. A comprehensive literature search was carried out to identify eligible studies from MEDLINE/PubMed and ClinicalTrials.gov. Expert opinion: A key hurdle to success in this field is our limited understanding of the synergic interactions of the immune targets in the context of the TME. While we can recognize the links between inhibitors and some particularly promising new targets such as TIM-3 and LAG3, we continue to develop approaches to exploit their interactions to enhance the immune response of the patient to tumor cells.
KW - CAR T
KW - GITR
KW - IDO
KW - immune checkpoint inhibitors
KW - immune modulators
KW - LAG3
KW - Non-small cell lung cancer
KW - NSCLC
KW - OX40
KW - TIGIT
KW - TIM-3
KW - VISTA
UR - http://www.scopus.com/inward/record.url?scp=85087887222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087887222&partnerID=8YFLogxK
U2 - 10.1080/13543784.2020.1793956
DO - 10.1080/13543784.2020.1793956
M3 - Review article
C2 - 32643447
AN - SCOPUS:85087887222
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
ER -